Cargando…

Enrichment of Aldolase C Correlates with Low Non-Mutated IDH1 Expression and Predicts a Favorable Prognosis in Glioblastomas

The aldolases family is one of the main enzymes involved in the process of glycolysis. Aldolase C (ALDOC), which belongs to the aldolase family, is found in normal brain tissue and is responsible for the repair of injured tissue. However, the role of ALDOC in glioblastoma remains unclear. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Yu-Chan, Tsai, Hsing-Fang, Huang, Shang-Pen, Chen, Chi-Long, Hsiao, Michael, Tsai, Wen-Chiuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770576/ https://www.ncbi.nlm.nih.gov/pubmed/31450822 http://dx.doi.org/10.3390/cancers11091238

Ejemplares similares

Overexpression of PSAT1 Gene is a Favorable Prognostic Marker in Lower-Grade Gliomas and Predicts a Favorable Outcome in Patients with IDH1 Mutations and Chromosome 1p19q Codeletion
por: Huang, Shang-Pen, et al.
Publicado: (2019)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

High FREM2 Gene and Protein Expression Are Associated with Favorable Prognosis of IDH-WT Glioblastomas
por: Jovčevska, Ivana, et al.
Publicado: (2019)

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
por: Stancheva, Gergana, et al.
Publicado: (2014)

Type V collagen alpha 1 chain promotes the malignancy of glioblastoma through PPRC1-ESM1 axis activation and extracellular matrix remodeling
por: Tsai, Hsing-Fang, et al.
Publicado: (2021)

BICD Cargo Adaptor 1 (BICD1) Downregulation Correlates with a Decreased Level of PD-L1 and Predicts a Favorable Prognosis in Patients with IDH1-Mutant Lower-Grade Gliomas
por: Huang, Shang-Pen, et al.
Publicado: (2021)

Distribution and favorable prognostic implication of genomic EGFR alterations in IDH ‐wildtype glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Nonenzymatic function of Aldolase A downregulates miR-145 to promote the Oct4/DUSP4/TRAF4 axis and the acquisition of lung cancer stemness
por: Chang, Yu-Chan, et al.
Publicado: (2020)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas
por: Huang, Shang-Pen, et al.
Publicado: (2017)

Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China
por: Yan, Wei, et al.
Publicado: (2012)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

The immune regulation of BCL3 in glioblastoma with mutated IDH1
por: Fan, Shibing, et al.
Publicado: (2022)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

IDH1 mutations in a Brazilian series of Glioblastoma
por: Uno, Miyuki, et al.
Publicado: (2011)

TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma
por: Kikuchi, Zensho, et al.
Publicado: (2020)

The prognostic IDH1(R132) mutation is associated with reduced NADP(+)-dependent IDH activity in glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2010)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco
por: Senhaji, Nadia, et al.
Publicado: (2017)

TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations
por: Arita, Hideyuki, et al.
Publicado: (2020)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

Bioinformatics analysis of the role of aldolase A in tumor prognosis and immunity
por: Tian, Wanjia, et al.
Publicado: (2022)

Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation
por: Liu, Aizhen, et al.
Publicado: (2016)

DNMT3A co-mutation in an IDH1-mutant glioblastoma
por: Fomchenko, Elena I., et al.
Publicado: (2019)

Increased RLIP76 expression in IDH1 wild-type glioblastoma multiforme is associated with worse prognosis
por: Wang, Qi, et al.
Publicado: (2020)

Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1(R132H) mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss
por: Cai, Hong-Qing, et al.
Publicado: (2018)

Engineering aldolases as biocatalysts()
por: Windle, Claire L, et al.
Publicado: (2014)

Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
por: van Noorden, Cornelis J.F., et al.
Publicado: (2021)

The NADP(+)-dependent IDH1 mutation and its relevance for glioblastoma patient survival
por: Van Noorden, Cornelis JF
Publicado: (2014)

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients
por: Amelot, Aymeric, et al.
Publicado: (2015)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
por: Yang, Pei, et al.
Publicado: (2015)

Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival
por: Wang, Peng-Fei, et al.
Publicado: (2017)

The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
por: Christians, Arne, et al.
Publicado: (2019)

IDH Mutations: Genotype-Phenotype Correlation and Prognostic Impact
por: Wang, Xiao-Wei, et al.
Publicado: (2014)

IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis
por: Zou, Peng, et al.
Publicado: (2013)

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status
por: Tabei, Yusuke, et al.
Publicado: (2020)

IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
por: Komrokji, Rami, et al.
Publicado: (2022)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
por: Tsai, Yu-Ling, et al.
Publicado: (2020)

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
por: Libura, Marta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7n5i9870601dfq2v121prltpdj